Skip to main content

Table 4 Antimicrobial activity against resistant respiratory Pseudomonas aeruginosa isolates by subset (ATLAS 2016–2018)

From: In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016–2018)

Organism Antimicrobial MIC (mg/L) %S + %Ia %R
MIC90 Range
P. aeruginosa,
MDR (n = 1281)
Piperacillin-tazobactam ≥256 ≤0.25–≥256 8.7 91.3
Aztreonam 128 0.12–≥256 36.5 63.5
Ceftazidime ≥256 0.06–≥256 19.1 80.9
Ceftazidime-avibactam 64 ≤0.015–≥256 62.9 37.1
Cefepime 32 0.5–≥64 19.1 80.9
Imipenem ≥16 ≤0.03–≥16 17.1 82.9
Meropenem ≥32 ≤0.06–≥32 38.6 61.4
Levofloxacin ≥16 ≤0.03–≥16 9.6 90.4
Colistin 1 ≤0.06–≥16 99.5 0.5
Amikacin 64 ≤0.25–≥128 61.3 38.7
P. aeruginosa,
carbapenemase positive/
MBL-negative (n = 53)
Piperacillin-tazobactam ≥256 16–≥256 3.8 96.2
Aztreonam ≥256 2–≥256 28.3 71.7
Ceftazidime ≥256 4–≥256 5.7 94.3
Ceftazidime-avibactam 32 1–≥256 71.7 28.3
Cefepime ≥64 4–≥64 15.1 84.9
Imipenem ≥16 8–≥16 0.0 100
Meropenem ≥32 8–≥32 3.8 96.2
Levofloxacin ≥16 0.5–≥16 5.7 94.3
Colistin 1 0.25–4 98.1 1.9
Amikacin 64 2–≥128 30.2 69.8
P. aeruginosa,
MBL-positive (n = 251)b
Piperacillin-tazobactam ≥256 4–≥256 5.6 94.4
Aztreonam 64 0.25–≥256 56.6 43.4
Ceftazidime ≥256 8–≥256 1.6 98.4
Ceftazidime-avibactam ≥256 2–≥256 2.8 97.2
Cefepime ≥64 8–≥64 4.4 95.6
Imipenem ≥16 4–≥16 0.8 99.2
Meropenem ≥32 4–≥32 3.2 96.8
Levofloxacin ≥16 0.5–≥16 1.6 98.4
Colistin 1 0.25–2 100 0.0
Amikacin ≥128 2–≥128 19.1 80.9
  1. MIC minimum inhibitory concentration; MIC90 MIC required to inhibit the growth of 90% of isolates; %S percent susceptible, standard dosing regimen; %I percent susceptible, increased exposure; %R percent resistant; MDR multidrug-resistant; MBL metallo-β-lactamase
  2. aIncludes all isolates not in the resistant category for all antimicrobial agents
  3. bIsolates in this subset are carbapenemase-positive and MBL-positive